Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Wang ES, Montesinos P, Minden MD, Sibai H, Lee JH, Heuser M, Naoe T, Chou WC, Laribi K, Esteve J, Altman JK, Havelange V, Watson AM, Fumagalli M, Patkowska E, Hill JE, Gill SC, Pandya BJ, Chen C, Hasabou N

Open source

DOI: 10.3324/haematol.2026.301112
Published: 2026 Sep 3
Container: Haematologica
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2026.301112,
  title = {Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.},
  author = {Wang ES and Montesinos P and Minden MD and Sibai H and Lee JH and Heuser M and Naoe T and Chou WC and Laribi K and Esteve J and Altman JK and Havelange V and Watson AM and Fumagalli M and Patkowska E and Hill JE and Gill SC and Pandya BJ and Chen C and Hasabou N},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2026.301112},
  url = {https://doi.org/10.3324/haematol.2026.301112}
}

RIS

TY  - JOUR
TI  - Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.
AU  - Wang ES
AU  - Montesinos P
AU  - Minden MD
AU  - Sibai H
AU  - Lee JH
AU  - Heuser M
AU  - Naoe T
AU  - Chou WC
AU  - Laribi K
AU  - Esteve J
AU  - Altman JK
AU  - Havelange V
AU  - Watson AM
AU  - Fumagalli M
AU  - Patkowska E
AU  - Hill JE
AU  - Gill SC
AU  - Pandya BJ
AU  - Chen C
AU  - Hasabou N
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2026.301112
UR  - https://doi.org/10.3324/haematol.2026.301112
ER  -

APA

ES, W., P, M., MD, M., H, S., JH, L., M, H., T, N., WC, C., K, L., J, E., JK, A., V, H., AM, W., M, F., E, P., JE, H., SC, G., BJ, P., C, C., & N, H. (2026). Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.. Haematologica. https://doi.org/10.3324/haematol.2026.301112

Source records

pubmed · retrieved 2026-09-26T16:27:33.121Z